Biology of schizophrenia: Is treatment refractoriness synonymous with severity of illness [A.K.A. is this a drug efficacy problem or an expression of severe illness?

Helio Elkis, Peter F. Buckley

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Approximately one-quarter of individuals develop schizophrenia in early childhood and adolescence. Typically, the course of illness in these patients is deteriorative. Moreover, longitudinal evaluation of chronic relapsing illness reveals evidence of neurodegenerative tissue loss. There is some evidence-albeit preliminary and somewhat controversial-that antipsychotic medications can obviate and/or ameliorate these changes. This chapter will describe the neurobiology of schizophrenia with a focus on the timing, evolution, and putative neurobiological correlates of treatment-refractoriness in schizophrenia.

Original languageEnglish (US)
Title of host publicationTreatment-Refractory Schizophrenia
Subtitle of host publicationA Clinical Conundrum
PublisherSpringer Berlin Heidelberg
Pages21-30
Number of pages10
ISBN (Electronic)9783642452574
ISBN (Print)9783642452567
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Biology of schizophrenia: Is treatment refractoriness synonymous with severity of illness [A.K.A. is this a drug efficacy problem or an expression of severe illness?'. Together they form a unique fingerprint.

  • Cite this